Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma has announced positive interim results from a Phase Ib trial of M701 for treating malignant pleural effusion in advanced non-small cell lung cancer, presented at ESMO Congress 2024. The study reported a favorable safety profile and promising efficacy rates, with a 61.5% response rate at week 4. These results have spurred the advancement to a Phase II study, aiming to further assess efficacy and safety compared to cisplatin.
For further insights into HK:2496 stock, check out TipRanks’ Stock Analysis page.